Literature DB >> 16581089

Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules.

Alan R Gintzler1, Sumita Chakrabarti.   

Abstract

Opioid desensitization/tolerance mechanisms have largely focused on adaptations that occur on the level of the mu-opioid receptor (MOR) itself. These include opioid receptor phosphorylation and ensuing trafficking events. Recent research, however, has revealed additional adaptations that occur downstream from the opioid receptor, which involve covalent modification of signaling molecules and altered associations among them. These include augmented isoform-specific synthesis of adenylyl cyclase (AC) and their phosphorylation as well as augmented phosphorylation of the G(beta) subunit of G(beta gamma). The aggregate effect of these changes is to shift mu-opioid receptor-coupled signaling from predominantly G(i alpha) inhibitory to (G(i)-derived) G(beta gamma) stimulatory AC signaling. Most recently, chronic morphine has been shown to enhance the association (interaction) between MOR and G(s), which should provide an additional avenue for offsetting inhibitory MOR signaling sequelae. The unfolding complexity of chronic morphine-induced sequelae demands an evolving broader and more encompassing perspective on opioid tolerance-producing mechanisms. This should facilitate understanding tolerance within the context of physiological plasticity that is activated by chronic exposure to drugs of abuse. Additional research is required to integrate the various tolerance-producing adaptations that have been elucidated to date. Specifically, the relative contribution to opioid tolerance of identified adaptations is still unknown as is the extent to which they vary among different regions of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581089     DOI: 10.1016/j.lfs.2006.02.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  22 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

2.  Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells.

Authors:  Christian Doll; Florian Pöll; Kenneth Peuker; Anastasia Loktev; Laura Glück; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 3.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

4.  Absence of μ opioid receptor mRNA expression in astrocytes and microglia of rat spinal cord.

Authors:  Sheng-Chin Kao; Xiuli Zhao; Chun-Yi Lee; Fidelis E Atianjoh; Estelle B Gauda; Myron Yaster; Yuan-Xiang Tao
Journal:  Neuroreport       Date:  2012-04-18       Impact factor: 1.837

Review 5.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

Review 6.  Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.

Authors:  Patrick M Regan; Rajnish S Dave; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

7.  Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.

Authors:  T A Barnes; J McDonald; D J Rowbotham; T L Duarte; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-25       Impact factor: 3.000

8.  Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat.

Authors:  Ziva D Cooper; Yen Nhu-Thi Truong; Yong-Gong Shi; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2008-05-30       Impact factor: 4.030

9.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors:  Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal:  J Pain       Date:  2008-05-12       Impact factor: 5.820

10.  Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

Authors:  K Blum; M Oscar-Berman; J Giordano; Bw Downs; T Simpatico; D Han; John Femino
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.